Levodopa/carbidopa subcutaneous - NeuroDerm
Alternative Names: Carbidopa/levodopa subcutaneous - NeuroDerm; ND-0612; ND-0612H; ND-0612L; ND-0680Latest Information Update: 11 Nov 2025
At a glance
- Originator NeuroDerm
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Parkinson's disease
Most Recent Events
- 23 Oct 2025 Mitsubishi Tanabe Pharma Corporation receives complete response letter from the US FDA for Levodopa/carbidopa in Parkinson’s disease
- 23 Oct 2025 NeuroDerm plans to resubmit the NDA to US FDA for Parkinson’s Disease
- 29 May 2025 FDA assigns PDUFA action date of third quarter 2025 for Levodopa/carbidopa subcutaneous for Parkinson's disease